<?xml version="1.0" encoding="UTF-8"?>
<p>We begin with the European Union (EU)’s regulatory system, arguably the world’s largest MRH program and the one most relevant to the EAC MRH initiative. The EU system oversees the regulation of medicines across some 30 European countries. It has existed in its current state since 1995 and provides 4 pathways by which drug manufacturers can apply for marketing authorization (
 <xref rid="pmed.1003092.t001" ref-type="table">Table 1</xref>) [
 <xref rid="pmed.1003092.ref008" ref-type="bibr">8</xref>]. The EU system consists of (1) the European Commission, which implements and oversees the legal basis for the system, ensuring that member states recognize the system’s decisions; (2) the European Medicines Agency (EMA), which oversees and coordinates the assessment of new medicines through the centralized procedure; and (3) the national agencies of EU member states, which carry out scientific assessments regardless of which marketing authorization procedure is used. The system’s decentralized procedure—in which an EU member state performs an initial evaluation of a medicine, which is then vetted by the other member states—is most akin to the EAC MRH’s joint assessment program.
</p>
